UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest event Reported): ~~September~~December 286, ~~2015~~2017

TARGETED MEDICAL PHARMA, INC.

(Exact name of registrant as specified in its charter)

DELAWARE	000-53071	20-5863618
(State or other jurisdiction of	(Commission	(IRS Employer
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification No.)
incorporation or organization)	File Number)	Identification No.)

2980 BEVERLY GLEN CIRCLE, SUITE ~~301~~100

LOS ANGELES, CA 90077

(Address of principal executive offices)

(310) 474-9808

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[¨ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [¨ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [¨ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [¨ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~Indicate by check mark whether the registrant ~~4.01~~is ~~Changes~~an emerging growth company as defined in ~~Registrant’s~~Rule ~~Certifying~~405 ~~Accountant~~of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

~~On September~~Emerging ~~29, 2015, Targeted Medical Pharma, Inc., a Delaware corporation (the “Company”), dismissed the Company’s~~growth independent registered public accounting firm, Marcum LLP (“Marcum”) effective immediately. The decision to dismiss Marcum was approved by the Audit Committee of the Board of Directors (the “Audit Committee”) of the Company on September 28, 2015. company ¨

~~In connection~~If ~~with~~an ~~the~~emerging ~~audits~~growth ~~of the fiscal years ended December 31~~company, ~~2014 and 2013 and through September 28, 2015, there were (i)~~indicate noby ~~disagreements~~check ~~with~~mark ~~Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements~~ if ~~not resolved to~~ the ~~satisfaction~~registrant ofhas ~~Marcum~~elected ~~would~~not ~~have caused them~~ to ~~make~~use ~~reference to~~ the ~~subject~~extended ~~matter~~transition ofperiod ~~the~~for ~~disagreement(s)~~complying ~~in connection~~ with ~~their~~any ~~report;~~new ~~(2)~~or norevised ~~“reportable~~financial accounting ~~events”~~standards asprovided ~~such~~pursuant ~~term is~~to ~~defined~~Section ~~in Item 304~~13(a)~~(1)(v)~~ of ~~Regulation~~the ~~S-K~~Exchange Act. ¨

~~Marcum’s report~~Item on5.02. ~~the~~Departure ~~financial statements~~ of ~~the~~Directors ~~Company~~or ~~for~~Certain ~~the~~Officers; ~~years~~Election ~~ended~~of ~~December~~Directors; ~~31,~~Appointment ~~2014 and 2013 did not contain an adverse opinion or a disclaimer~~ of ~~opinion,~~Certain ~~nor~~Officers; ~~was~~Compensatory itArrangements qualified or modified as to uncertainty, audit scope, or accounting principles except that both reports stated there is substantial doubt about the Company’s ability to continue as a going concern due to the Company’s financial condition as of ~~December~~Certain ~~31, 2014 and December 31, 2013~~Officers.

~~The Company~~On ~~has~~December ~~provided~~6, ~~Marcum~~2017, ~~with~~Mr. aKim ~~copy~~Giffoni oftendered ~~this~~his resignation ~~Form~~as ~~8-K~~Interim ~~prior~~Chief toExecutive ~~its~~Officer ~~filing~~of ~~with~~Targeted ~~the~~Medical ~~Securities~~Pharma, ~~and~~Inc. ~~Exchange Commission~~ (the “~~SEC~~Company”) to focus on other business activities. At the time of his resignation, ~~and~~Mr. ~~has~~Giffoni ~~requested~~served ~~that~~as ~~Marcum~~Interim ~~furnish~~Chief Executive Officer and Director. Mr. Giffoni will remain a ~~letter~~member ~~addressed~~of tothe Company’s Board and will serve as the ~~SEC~~Company’s ~~stating~~Executive ~~whether~~Vice President itof ~~agrees~~Foreign Sales. Mr. Giffoni did not resign as a result of any disagreement with the ~~above~~Company on any matter ~~statements~~relating ~~and,~~to ifthe ~~not~~Company’s operations, ~~stating~~policies or practices. Indicate by check mark whether the ~~respects~~registrant is an emerging growth company as defined in ~~which~~Rule it405 ~~does~~of ~~not~~the ~~agree~~Securities Act of 1933 (§230.405 Aof ~~copy~~this chapter) or Rule 12b-2 of the ~~such~~Securities ~~letter,~~Exchange ~~dated~~Act ~~October~~of 1,1934 ~~2015,~~(§240.12b-2 ~~indicating~~of this chapter).Emerging growth company ¨If an emerging growth ~~that~~company, itindicate isby incheck ~~agreement~~mark if the registrant has elected not to use the extended transition period for complying with any ~~such~~new ~~disclosures~~or isrevised ~~filed~~financial asaccounting ~~Exhibit~~standards ~~16.1~~provided pursuant to ~~this~~Section ~~Form~~13(a) ~~8-K~~of the Exchange Act.

~~On September~~An ~~29,~~interim ~~2015,~~Chief ~~the~~Executive ~~Company engaged Squar Milner~~Officer, ~~LLP~~Marcus ~~as the Company’s independent registered public accounting firm effective immediately. The engagement was approved by the Audit Committee on September 28~~Charuvastra, ~~2015. Prior to September 28, 2015, neither~~ the ~~Company nor anyone acting on its behalf consulted with Squar Milner, LLP regarding (1) the application of accounting~~ ~~principles to a specified transaction, either completed or proposed, (2) the type of audit opinion that might be rendered on the~~ Company’s ~~financial~~former ~~statements,~~VP (3) written or oral advice provided that would be an important factor considered by the Company in reaching a decision as to an accounting, auditing or financial reporting issue, or (4) any matter that was the subject of aOperations ~~disagreement~~and ~~between~~Marketing ~~the Company~~ and ~~its predecessor auditor as described in Item 304(~~a~~)(1)(iv)~~ orcurrent aDirector ~~reportable~~has ~~event~~been ~~as described~~appointed inby ~~Item~~the ~~304(a)(1)(v) of Regulation S-K~~board.

~~The Company has authorized Marcum to respond fully to any inquiries of Squar Milner, LLP.~~2

~~Item 9.01 Financial Statements and Exhibits.~~SIGNATURES

~~(d)~~Pursuant ~~Exhibits~~to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~The~~Dated: ~~following exhibits~~December ~~are~~12, ~~filed with this Current Report on Form 8-K:~~2017

Exhibit No.		Description
16.1		Letter to the Securities and Exchange Commission from Marcum LLP dated October 1, 2015.

	TARGETED MEDICAL PHARMA, INC.


	By: /s/	Marcus Charuvastra
		Name: Marcus Charuvastra
		Interim Chief Executive Officer

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 1, 2015

TARGETED MEDICAL PHARMA, INC. By: /s/ William B. Horne Name: William B. Horne Chief Financial Officer

Filing Compare · Targeted Medical Pharma, Inc.